Basic Information
LncRNA/CircRNA Name | HCG22 |
Synonyms | NA |
Region | GRCh38_6:31053450-31059890 |
Ensemble | ENSG00000228789 |
Refseq | NA |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | Drug | |||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | bladder cancer |
ICD-0-3 | C67 |
Methods | qPCR, Western blot, RIP |
Sample | healthy bladder immortalized cell line (SV-HUC-1) and cancerous cell lines (J82, T24, SW780, TCC, EJ), BCa tissues and matched adjacent healthy ones |
Expression Pattern | down-regulated |
Function Description | lncRNA HLA complex group 22 (HCG22) was weakly expressed in BCa samples and lowly expressed HCG22 was closely correlated with low overall survival of the BCa patient. To verify the role of HCG22 in BCa progression, functional experiments were carried out in two representative BCa cells (J82 and T24) and the negative effects of HCG22 expression on the cell proliferation, migration, and epithelial-mesenchymal transition were identified. Mechanistically, polypyrimidine tract-binding protein 1 (PTBP1), which was highly expressed in BCa tissues and cell lines, was negatively regulated by HCG22 and the PTBP1-mediated Warburg effect was also obstructed by HCG22. Furthermore, HCG22 modulated the expression of PTBP1 through destabilizing human antigen R (HuR). And functional rescue assays confirmed that HCG22 functioned in bladder cancer through downregulating PTBP1. |
Pubmed ID | 31304601 |
Year | 2019 |
Title | Long noncoding RNA HCG22 suppresses proliferation and metastasis of bladder cancer cells by regulation of PTBP1 |
External Links
Links for HCG22 | GenBank HGNC NONCODE |
Links for bladder cancer | OMIM COSMIC |